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Proteinase inhibitors reduce basement membrane
degradation by human breast cancer cell lines
PS Stonelake1 2, CE Jones', JP Neoptolemos1 and PR Baker1
'Department of Surgery, University of Birmingham, Queen Elizabeth Hospital, Birmingham Bi 5 2TH; 2City Hospital NHS Trust,
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Summary The relative importance of different proteinases, and their inhibition, in the breakdown of human endothelial basement membrane
(BM) by MDA-MB-231 and MCF7ADR human breast cancer cell lines has been studied using 35S-labelled BM-coated 96-well culture plates.
Basement membrane degradation (BMD) was independent ofcell proliferation above the seeding density. Inhibitors ofaspartic (pepstatin and
PD 134678-0073) and cysteine proteinases (E64) had little effect on BMD under normal culture conditions, suggesting that cathepsins D, B
and L have only a minor role. In contrast, inhibitors of urokinase-type plasminogen activator (uPA) and/or plasminogen activation to plasmin
(aprotinin, amiloride, EACA, tranexamic acid, anti-uPA antibody) all reduced BMD by MDA-MB-231 cells by approximately 30-40%, but only
in the presence of serum or plasminogen. BB94, an inhibitor of matrix metalloproteinases (MMPs), also reduced BMD by about 30% under
these conditions but was similarly effective in serum-free medium. Combinations of BB94 with any of the uPA/plasminogen activation
inhibitors in serum-containing medium had additive effects, while BB94 with pepstatin and E64 under serum-free conditions reduced BMD to
16% of control. Serum-containing conditioned medium exhibited appreciable BMD, largely due to aprotinin-inhibitable activity. Although small
reductions in cell proliferation were seen with some inhibitors, the combination of BB94with E64 or E64d reduced the cell population by about
60% under serum-containing conditions. These in vitro observations suggest that combinations of proteinase inhibitors, particularly of
uPA/plasminogen activation and MMPs, may merit clinical evaluation as potential antimetastatic therapy for breast cancer.
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The mortality from breast cancer, as with other malignancies, is
principally due to the spread of primary tumour cells by invasion
and metastasis. Basement membranes (BM) are barriers to the
spread of cancer cells whether by local invasion into tumour
stroma, intravasation of lymphovascular structures or distant
extravasation and metastasis formation (Fidler, 1990). Basement
membrane degradation (BMD) is brought about by extracellular
proteinases, and there is currently interest in inhibitors of these
enzymes as potential therapeutic agents. Possible candidates for
the proteinases involved in breast cancer invasion are found in
each ofthe fourmajorclasses ofproteinases, i.e. aspartic,cysteine,
serine and matrix metalloproteinases (MMPs).
The aspartic proteinase cathepsin D, alysosomal enzyme, is over-
secretedbybreast cancercells invitroandmaybe amajorproteinase
involved in BMD (Briozzo et al, 1988). This view is supported by
in vivo experiments in which transfection of cathepsin D cDNA
resulted in a higher frequency of metastases in mice (Garcia et al,
1990). Nevertheless, some workers have questioned whether this
lysosomal enzyme, which is only active at acid pH, has a role in
invasion underphysiological conditions (Johnson et al, 1993).
The cysteine proteinases, cathepsins B, L and H, are also lyso-
somal enzymes that are overexpressed in breast cancer (Vasishta et
al, 1988; Gabrijelcic et al, 1992). Cathepsin B from normal human
liverand from human breast carcinomas has been shown to degrade
components ofBM at neutral pH as well as at acid pH (Buck et al,
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1992) and is associated with invasive potential ofmetastatic murine
cell lines (Rozhin et al, 1990). Furthermore, malignant progression
of human breast epithelial and colorectal carcinoma cell lines, as
well as the murine melanoma cells, is accompanied by peripheral
redistribution of cathepsin B within the cells and increased secre-
tion ofthe active proteinase (Rozhin et al, 1994).
The serine proteinases and MMPs areoptimally active at neutral
pH and may therefore play a central role in cancer cell invasion.
Of the former class, urokinase-type plasminogen activator (uPA)
has been shown to be required for the invasion of several malig-
nant cell types in vitro (Mignatti etal, 1986; Kobayashi et al, 1992;
Reiter et al, 1993). Type IV collagenases are expressed in breast
cancer (Monteagudo et al, 1990; Davies et al, 1993a), and there is
accumulating evidence that MMPs are important in the invasion
and metastasis ofmalignant cells (Mignatti et al,1986; Reich et al,
1988; Davies et al, 1993b).
For the most part, these proteinases have been studied in isola-
tion, although each enzyme is produced as an inactive proenzyme
requiring activation by other proteinases. Therefore, in addition to
any direct action on BM by individual proteinases, a proteolytic
cascade mechanism is also involved (Mignatti et al, 1986; Reich
et al, 1988; Schmitt et al, 1992).
Clearly, in the development ofproteinase inhibitors as potential
anti-cancer agents, it is important to know which are the major
proteinases to be targeted. There has, however, been no previous
investigation into the relative roles of these different types of
proteinases in breast cancer invasion. The aim ofthis study was to
establish, in an in vitro model of BMD by breast cancer cells, the
relative contributions ofthese proteinases by the use of inhibitors.
This approach might also suggest the potential of these inhibitors
fordevelopment as therapeutic agents.
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MATERIALS AND METHODS
Cell lines and culture conditions
The breast cancer cell lines used in this study were the oestrogen
receptor (ER)-negative MDA-MB-231 cells (ATCC, USA) and the
doxorubicin-resistant ER-negative MCF7 variant MCF7 DOX
(Beatson Institute, Glasgow, UK). Comparative data are presented
forthe ER-positive cell lines,wild typeMCF7w (Beatson Institute),
ZR75 (Dr Robert Clarke, Lombardi Cancer Research Centre,
Washington DC, USA) and T47D (ECACC, UK) and the ER-nega-
tive cell lines Hs578T, Hs578Bst (ATCC) and BC8701 (Minafra et
al, 1989; derived from primary tumour). The cell lines were main-
tained at 370C in Dulbecco's modified Eagle's medium (DMEM)
with 5% fetal calf serum (FCS) and added non-essential amino
acids, glutamine (2 mM), penicillin (100 U ml-') and streptomycin
(100 [tg ml-'); all reagents were from ICN-Flow (High Wycombe,
UK). This medium was also used as the experimental medium for
the invasion assay for serum-containing (SC) conditions or with the
FCS replaced by 0.5% bovine serum albumin fraction V (Sigma,
Poole, UK) for serum-free (SF) conditions. In some experiments,
the SF medium was supplemented with human plasminogen
(Sigma; plasmin- and EACA-free) in 50 mM Tris/0.1 M sodium
chloride buffer pH 7.0 at a final concentration of 50 ng ml-'. Cells
for the invasion assay were lifted with 1 mM EDTA, avoiding
trypsin, washed with phosphate-buffered saline (PBS) and DMEM,
and the cell density was determined by Coulter counting.
Endothelial cell culture
Human umbilical vein endothelial cells were harvested and estab-
lished in primary culture as previously described by our laboratory
(Mosquera et al, 1991). Briefly, fresh human umbilical cords
were obtained, the vein flushed with PBS and then incubated with
150 U ml-' collagenase (Worthington Biochemical, Twyford, UK)
for 15 min at 370C. Detached endothelial cells were then flushed
from the vein, centrifuged and cultured in gelatin-coated flasks in
199 medium (Ml99) with 20% FCS, L-glutamine (2 mM), strepto-
mycin (100 [tg ml-'), penicillin (100 U ml-'), endothelial cell
growth factor (150 tg ml-') and 50 U ml-' preservative-free
heparin (complete M199).
BMD invasion assay
Preparation ofthe radiolabelled BM
The invasion assay was developed from the original radiolabelled
subendothelial basement membrane model described by Yee and
Shui (1986) but with important modifications, including the use of
a 96-well culture plate format and correction for log-phase cell
proliferation. Human umbilical vein endothelial cells were seeded
at 5 x 103 cells per well into the central 60 wells of a gelatin-coated
96-well culture plate (Nunc, Gibco, UK) in complete M199 with
added ascorbate (50 itg ml-'). The outer wells were filled with PBS
for humidification. After 48 h, the medium was changed in the
upper 30 wells with methionine- and cysteine-deficient DMEM
containing 20% FCS, L-glutamine (2 mM), streptomycin (100 [tg
ml-'), penicillin (100 U ml-'), endothelial cell growth factor
(150 [tg ml-), 50 U ml-' of preservative-free heparin, 50 ig ml-'
fresh sodium ascorbate and [35S]methionine (ICN Flow 'Trans-
label') added at 25 iCi ml-'. Medium in the lower 30 wells was
replaced with fresh unlabelled medium; these wells were used to
recover the breast cancer cells for Coulter counting. After 6 days'
incubation at 37°C, the endothelial cells were lysed and washed
away with fourvigorous washes in sterile water and two with PBS,
leaving a radiolabelled BM firmly adherent to the bottom of each
well. Absence of endothelial cells was checked by phase-contrast
microscopy, and scanning electron microscopy (SEM) ofrepresen-
tative plates confirmed that the BM was free of cells and debris.
The BM composition was not characterized in this study although
this has been previously established (Yee and Shui, 1986).
BMD bybreast cancercells
The BM-coated plate was washed repeatedly with PBS before
setting up the assay to ensure removal of non-BM-incorporated
radioactivity. The assay was performed in triplicate with the
central 60 BM-coated wells used as 10 columns of 6 wells, the
upper three for BMD and the lower three for cell proliferation. SC
or SF experimental medium (100 jtl) containing vehicle only
(columns 1 and 2) or proteinase inhibitors (columns 3-10) was
added to the empty wells and the plate was preincubated for 1 h.
Breast cancer cells, grown in experimental medium (SC or SF) for
at least 3 days, were seeded into fresh experimental medium and
100 ,ul containing approximately 20 000 cells was added to each
well, except column 1 wells which received medium only (back-
ground control). SF conditions had no apparent effect on plating
efficiency although growth was slower. After 72 h incubation at
37°C, the medium was removed from each of the upper 30 wells
and placed in individual vials containing 1 ml ofHisafe III scintil-
lation fluid. The wells were washed gently with 100 itl of PBS
which was added to the vials. This radioactivity represented solu-
bilized or degraded BM. The residual BM in the wells was then
solubilized by overnight incubation with 100 p1 of 0.1% collage-
nase (277 U ml', Worthington Biochemicals) and 0.25% trypsin
(1:250, Difco) in PBS and added, together with a PBS wash, to
another set of vials containing 1 ml of scintillation fluid. Vials
were counted in a LKB ,8-counter. Total radiolabelled BM in
each well was obtained from the two sets of counts. The cell
numbers associated with the BMD, after the 3-day incubation,
were obtained from the lower set of 30 wells. The medium was
removed from the wells, which were then washed gently with
PBS, and cell nuclei were released with 200 [tl per well of Hepes
buffer containing two drops per ml of zaponin (Coulter
Electronics, UK) and incubated for 20 min. After thorough
mixing, the nuclei/zaponin solution from each well, plus a further
200 tl ofwash, was added to 5 ml offormol saline, and the nuclei
were counted in a Coulter counter.
The percentage radioactivity released into solution was calcu-
lated for each well as follows:
solubilized or degraded BM 100
total radiolabelled BM
Values for control (no inhibitor, column 2) and experimental
media (inhibitors, columns 3-10) were corrected by subtraction of
the background (column 1) to give the corrected percentage
radioactivity released (D). Typically, background values for SC
and SF conditions were <10%; this may represent non-specific
release of radioactivity under the culture conditions. BMD was
then calculated from D using the following equation:
BMD = e[InD(InNlnC)]
where N is 20 000 (representing the number of cells seeded per
well) and C is the observed cell counts per well; ln is the natural
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Figure 1 BMD by MDA-MB-231 cells under SC conditions: (A) the effect of
duration of incubation on corrected percentage radioactivity released (D, O),
BMD (0) and cell population (x). Data points are means oftriplicate wells;
(B) the effect of cell population on D(corrected percentage radioactivity
released, i.e. without adjustment for cell numbers; E) and BMD (0). The data
points are means of cell counts after a 72-h incubation obtained from three
independent experiments (triplicate wells) in which cells were initially seeded
in SC medium at different densities (see Materials and methods for details of
calculation of Dand BMD)
logarithm and e is the constant base (= 2.7183). This procedure
provides a measure ofBMD that is normalized to 20 000 cells and
thereby corrects for differences in cell proliferation (log-phase
growth) between the experimental groups over the assay period. It
was found to be independent of the number of cells per well over
the range 20-140 x 103 and ofthe incubation period overthe range
48-120 h (Figure 1).
BMD is therefore defined as the percentage of the total BM
degraded over 3 days per 20 000 cells. As the number of experi-
ments completed for each inhibitor varied, to avoid bias, results
are generally presented as percentage of control BMD, although
'absolute' BMD values for controls and key inhibitors are given in
the text and legends.
BMdegradation bycell-conditioned medium (CM)
Serum-containing conditioned medium (SC-CM) from cultures of
MDA-MB-231 and MCF7 DOXcells were prepared by two different
procedures: (a) CM was collected from uncoated 75-cm2 plastic
flasks incubated for 16 h with SC medium, centrifuged at640 g for
5 min, filtered (0.2 FtM) and stored frozen at -20°C before BMD
assay; (b) BM-coated 96-well plates were set up as for routine
BMD assay except that MDA-MB-231 or MCF7DOX cells were
dispensed in fresh SC medium into all 60 central wells without
inhibitors. After three days, 150 ptl of CM from each well was
pooled, centrifuged, filtered as above andused immediately forthe
BMD assay.
In both cases, the BMD assay was performed as detailed above,
substituting CM for cells in fresh medium. Background wells
(column 1) received fresh medium only. BM degradation was
expressed as background-corrected percentage radioactivity
released (D) or percentage of the CM-only control, as adjustment
for cell proliferation was generally not appropriate. However,
representative cell counts per well for experiment (b) were
obtained to enable calculation of BMD for comparison with cell-
associated values.
Potential cathepsin D activity and its inhibition with pepstatin
were assessed by using serum-free CM (SF-CM) obtained from
MDA-MB-231 cell culture and subsequently adjusted to pH 3.0,
4.5 and 6.0 with 200 mm citric acid (Briozzo et al, 1988) before
assay. BM degradation was expressed as for the other CM experi-
ments. SF-CM at normal culture (pH 7.4) had very low activity on
BM and was not used for other studies.
Proteinase inhibitors
Inhibition ofasparticproteinases
Pepstatin (Cambridge Research Laboratories, Cambridge, UK), in
dimethyl sulphoxide (DMSO), was used as a well-established
inhibitorofcathepsin D (Barrett, 1977). Someexperiments were also
performed with the synthetic water-soluble renin and cathepsin D
inhibitor PD 134678-0073 (a gift from Parke-Davis Pharmaceutical
Research, MJ,USA; compound 9 in Doherty et al, 1992).
Inhibition ofcysteineproteinases
Theepoxysuccinyl peptides E64(Cambridge ResearchLaboratories)
andE64d (agift from Dr MTamai,Taisho Pharmaceutical, Saitama,
Japan), in DMSO, were selected for inhibition of cysteine pro-
teinases, such as cathepsins B and L (Barrett etal, 1982; Shoji-Kasai
et al, 1988).
Inhibition ofuPA andplasminogen activation
Aprotinin (Sigma), in 50% ethanol, was used as ageneral inhibitor
of serine proteinases, although it has higher affinity (x103) for
plasmin than uPA (Fritz andWunderer, 1983). Forthe inhibition of
specific sites in the activation of plasminogen to plasmin, a
number of inhibitors were used. r-amino-caproic acid (EACA;
Sigma) and tranexamic acid (Sigma), in 50% ethanol, bind to a
high-affinity site on the A,orheavy,chain ofplasminogen, thereby
inhibiting the activation of plasminogen and/or binding of the
proteinase to the cell surface, and thence pro-uPA activation
(Alkjaersig et al, 1959; Miles and Plow, 1985; Stephens et al,
1989). Amiloride (Sigma), in DMSO, and a rabbit polyclonal anti-
human uPA antibody (Ab-uPA) (kindly provided by Dr Peter
Andreason, University of Aarhus, Denmark) are selective
inhibitors of uPA, thereby preventing activation of plasminogen,
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Figure 2 The effect of inhibitors of uPA, plasminogen activation and MMPs
on BMD (percentage of control) by MDA-MB-231 cells under SC conditions.
Aprot or A, aprotinin (100 tg ml-' - 15.4 rtM); EACA, r-aminocaproic acid
(3.8 mM), Trnx, tranexamic acid (100 gM); Amil, amiloride (100 RM); Ab-uPA,
anti-uPA antibody (20 1tg ml-'); B, BB94 (2 gM); P, pepstatin (100 FtM); E, E64
(100 FM). Data (mean ± s.d.) were derived from the number of experiments
shown at the foot of each column and expressed as percentage of control
(Ctrl) for these experiments. Control BMD was 24.2 ± 5.0 (n = 21). Significant
differences from ANOVA with the Student-Newman-Keuls test at the
P < 0.05 level or lower are shown versus control (*) orcontrol and BB94 (*)
(see Materials and methods for further details)
but are not effective against plasmin (Vassalli and Belin, 1987;
Stephens et al, 1989). The antibody, supplied in phosphate buffer
with sodium azide, was dialysed overnight against 10 mm sodium
phosphate buffer in 150 mm sodium chloride pH 7.4. Non-immune
rabbit immunoglobulin (Sigma) in the same buffer was used as a
control.
Inhibition ofMMPs
The synthetic class specific inhibitor, BB94 (Davies et al, 1993b),
reconstituted in DMSO, and, in a limited number of experiments
only, recombinant TIMP-2, in 50% ethanol, were used as
inhibitors of MMPs (both inhibitors were gifts from British
Biotech, Oxford, UK).
The concentrations of inhibitors used were based upon
dose-response data obtained from initial experiments or from
published reports (above references). Details are given in the
Results section and legends to Figures and Tables. The amounts of
non-aqueous vehicle added perinhibitor to the experimental media
were (v/v) 0.1% or 0.5% for DMSO and 0.25% for ethanol (0.5%
for TIMP-2). In order to avoid the need for multiple controls per
96-well plate, all 60 wells received the same total vehicle addition
(volume and type), including the background and control wells.
The vehicle cocktail varied between experiments, but no effects on
control BMD or cell growth were apparent. The inhibitors per se,
incubated with freshly prepared SC medium, did not reduce BMD
but resulted in small increases in the percentage release ofradioac-
tivity ranging from 107% of control for amiloride to 119% of
control for aprotinin and the combination of BB94, aprotinin,
pepstatin and E64 (means oftwo experiments). The reason for this
observation is unknown but, as the effect was similar for all the
inhibitors and combinations and did not contribute to the reduction
in BMD observed with cells and CM, results were not corrected.
Methylene blue cell proliferation assay
In addition to Coulter counting of cells as part ofthe BMD assay,
the growth effects of the proteinase inhibitors were also assessed
using the methylene blue assay (Scragg and Ferreira, 1991).
Experimental conditions were identical to those used in the BMD
assay for SC medium, except that cells were seeded (20 x 103 per
well) into uncoated 96-well plates, and 6 wells were used for each
experimental group. The plates were read at 620 nm using a
microplate reader (Multiskan Bichromatic with Flexicalc soft-
ware, Labsystems, Basingstoke, UK), and the results were
presented as percentage ofabsorbance ofcontrol wells.
Data analysis
All statistical analysis was performed using SPSS for Windows
release 5.0 (SPSS,Chicago, IL, USA). Data from all experimental
groups were analysed by one-way analysis of variance (ANOVA)
with the Student-Newman-Keuls test for multiple pairwise
comparisons. Results are presented as mean ± s.d. unless other-
wise stated.
RESULTS
Comparison of BMD by breast cancer cell lines
Under SC conditions, MDA-MB-231 cells produced the highest
level of BMD (24.2 + 5.0, n = 21) and appreciable activity was
seen with MCF7DOX (8.0 ± 1.8, n = 15) and Hs578T (10.2 + 0.7,
n = 3) cells. In contrast to these ER-negative cell lines, the ER-
positive lines,MCF7VT, T47D and ZR75, had low activities (mean
values of approximately 2). Similar results were observed for the
BC8701 cell line, which had a primary tumour origin, while the
benign Hs578Bst cells did not degrade BM. In the absence of
serum, lower levels of BMD by MDA-MB-231 cells were
obtained (12.0 ± 3.3, n = 16). In view ofthese findings, the MDA-
MB-231 cell line was selected forthis study underboth SC and SF
conditions, although some experiments were also performed with
theMCF7DOX cell line under SC conditions only.
Cell-associated BMD
Inhibition ofaspartic andcysteineproteinases
Pepstatin or E64 (100 FiM) produced no significant reduction in
BMD by MDA-MB-231 or MCF7DO cells under SC conditions.
Under SF conditions (MDA-MB-231 cells), pepstatin was also
ineffective but some apparent reduction in BMD was seen with
E64 (84 ± 14%, n = 5) and pepstatin plus E64 (64 ± 13%, n = 4),
but this was not statistically significant using the multiple compar-
isons method. PD 134678-0073 (PD) produced no reduction in
BMD with these cells, although this inhibitor had to be used at a
lower concentration (10 FtM) because it was cytotoxic at 100 [tM.
Inhibition ofuPA, plasminogen activation andMMPs
BMD by MDA-MB-231 cells in SC medium was inhibited
30-40% by all the inhibitors of uPA and plasminogen activation,
andby BB94, when given as single agents (Figure 2). In a separate
series of experiments, lower concentrations of EACA (100 .LM)
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Figure 3 The effect of inhibitors of uPA, plasminogen activation and MMPs
on BMD (percentage of control) by MCF7DOX cells under SC conditions.
Control BMD was 8.0 + 1.8 (n = 15). For other details, see legend to Figure 2
also inhibited BMD by these cells (56 + 14.7% control, n = 3).
Control BMD was reduced from 24.2 ± 5.0 (n = 21) to 15.1 ± 5.8
(n = 14) by aprotinin and 17.6 + 4.8 (n = 14) by BB94, repre-
senting mean decreases of 9.1 and 6.6 respectively. When BB94
was given with any of the uPA or plasminogen activation
inhibitors under SC conditions, the effects were additive with
63-76% inhibition of BMD (mean BMD ranging from 5.9 to 9.3),
but the remaining activity was not inhibited by the inclusion of
pepstatin and E64 (Figure 2). However, findings from a single
experiment in which all combinations of BB94, aprotinin,
pepstatin and E64 were tested showed that BB94 plus E64 reduced
BMD below that seen with BB94 alone (53% vs 74% of control),
Table 1 The effects of proteinase inhibitors on SC-CM-mediated BM
degradation (D) as percentage of control
CM (plastic)a CM (BM)b
Inhibitor MDA-MB- MCF7DOX MDA-MB- MCF7DOX
231 231
BB94 96 ± 28 89 30 123 38
Aprotinin 1.1 ±2.5 -1.9 ±5.0 8 19
Pepstatin 112 106 130 78
E64 144 107 139 59
BB94 + aprotinin ND ND -15 31
BB94+ E64 ND ND 144 25
Pepstatin + E64 ND ND 138 82
B+A+P+Ec ND ND -38 -8
Data are means ± s.d. of three independent experiments or mean of two
independent experiments. aCM from cells grown on uncoated plastic flasks.
bCM from cells grown on BM-coated 96-well plates. cCombination of BB94,
aprotinin, pepstatin and E64. ND, not done.
Figure 4 The effect of inhibitors of uPA, plasminogen activation and
MMPs on BMD (percentage of control) by MDA-MB-231 cells under SF
conditions. Control BMD was 12.0 ± 3.3 (n = 16). For other details, see
legend to Figure 2
although the effect was less than with aprotinin (44%) and BB94
plus aprotinin (18%). WithMCF71OX cells, the inhibition of BMD
was less marked, with significant reductions in activity only
obtained with aprotinin and BB94 plus aprotinin (Figure 3).
In SF medium, the inhibitors of uPA/plasminogen activation
were ineffective in reducing BMD by MDA-MB-231 cells, while
BB94 reduced BMD from 12.0 + 3.3 to 5.3 ± 2.6 (n = 8), a similar
mean decrease (6.7) to that seen under SC conditions, although it
represents a 60% inhibition of control (Figure 4). Thus, in the
absence of plasminogen (i.e. SF medium) the uPA/plasminogen
activation component ofBMD is inactive. This was confirmed in a
separate experiment in which the addition of plasminogen (50 ng
ml-1) to MDA-MB-231 cells in SF medium increased BMD from
11.5 ± 1.6 (triplicate wells) to 26.2 ± 0.9, a level similar to that
seen under SC conditions. Preincubation with Ab-uPA (20 ,tg
ml-1) before addition of plasminogen prevented this increase
(BMD = 12.4 ± 0.9). While the combination BB94 and aprotinin
produced no further decrease in BMD by MDA-MB-231 cells
Table 2 The effect of pepstatin (100 RM) on BMD by SF-CM at different pH
levels
pH 3.0 4.5 6.0 7.4
CM onlya -1.3 10.1 4.5 3.2
CM + pepstatina -1.7 0.1 4.6 3.6
Pepstatin-inhibitable BMD -0.4 10.0 -0.1 -0.4
aData are means of triplicates. (Calculation of D involved subtraction of
background activity at each pH level as the amount of BM degraded was pH
dependent).
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Table 3 The effects of proteinase inhibitors on cell proliferation of MDA-MB-
231 cells under SC and SF conditions (percentage of control)
Inhibitora SC medium SF medium
BB94 So + 9 (14) 99 11 (8)
Aprotinin 101 ±5 (14) 103 4 (6)
Pepstatin 96 ± 2 (6) 94 ± 2 (5)
E64 98 ± 4 (6) 95 3 (5)
Pepstatin + E64 87 ± 8 (5) 89 ± 2 (4)
B+A+P+Eb 36 ± 9 (3)c 64 ± 7 (3)d
Data are mean ± s.d. for the number of independent experiments shown in
parentheses. aConcentrations of inhibitors are as given in the legend to
Figure 2. bB+A+P+E = the combination of BB94, aprotinin, pepstatin and
E64. cCell numbers were significantly different (P < 0.05) from control,
aprotinin, pepstatin and E64. dCell numbers were significantly different (P<
0.05) from control and aprotinin.
under SF conditions than was seen with BB94 alone, the addition
of pepstatin and E64 to this combination reduced BMD to 1.8 +
0.3 (n = 3) or only 16% of control (Figure 4). This is consistent
with the effect of pepstatin plus E64 in SF medium. On the other
hand, the endogenous MMP inhibitor TIMP-2 at 10 ItM was rela-
tively ineffective (11.0 ± 4.2% or 76 ± 11% ofcontrol, n = 3).
CM-mediated BM degradation
SC-CM obtained from MDA-MB-231 and MCF7DOX cell cultures
on uncoated plastic exhibited appreciable BM degradation which
was completely inhibited by aprotinin but not by BB94, pepstatin
or E64 (Table 1). A similar profile was observed for SC-CM from
MDA-MB-231 cells grown on BM-coated plates and, in addition,
combinations ofinhibitors containing aprotinin also prevented BM
degradation (Table 1). Inhibitors, apart from aprotinin, tended to
increase BM degradation while combinations containing BB94
and aprotinin reduced activity below control levels. The activity of
inhibitors on SC-CM from MCF7DOX cells grown on BM differed
in two respects: aprotinin and aprotinin plus BB94 effects were
less pronounced and the other inhibitors and combinations
appeared to reduce activity (Table 1). Values of D for controls
were: MDA-MB-231,6.1; andMCF7DOX 7.2 (means oftwo exper-
iments). The equivalent BMD values, using the representative cell
counts associated with the production ofthe CM, were 5.5 and 6.3
respectively, and compare with mean cell-associated BMD values
of24.2 and 8.0 (see above).
When SF-CM from MDA-MB-231 cells was adjusted to
different pH levels pepstatin-inhibitable BMD was only increased
at pH 4.5 (Table 2).
Effects of proteinase inhibitors on cell proliferation
In the absence ofinhibitors, MDA-MB-231 cell numbers per well
increased over the 3-day incubation period on BM-coated 96-well
plates from 20 x 103 (seeding density) to 63 ± 14 x 103 (n = 21)
under SC conditions, and to 33 ± 6 x 103 (n = 16) in SF medium.
Apart from amiloride under SC conditions and TIMP-2 under SF
conditions, in which cell numbers decreased to 78 + 20% (n = 5)
and 85 ± 9% (n = 3) of control counts respectively, single
inhibitors had minimal effect on cell proliferation at the concentra-
tions used for the BMD assay (see Table 3; other inhibitors not
shown had means of98% to 104% ofcontrol). While BB94 alone,
BB94 plus aprotinin and pepstatin plus E64 reduced mean cell
- o 0 _ 0. o a - 0 o o _0 0 WU - O X -LU T.- O LLU U a u + LU 4. L LUi m
+ m + LU
+ m
Figure 5 Effect of BB94 (B) at 2 FM and E64 (E) or E64d (Ed) at 1, 10 and
100 pM on MDA-MB-231 cell proliferation after 72 h on uncoated 96-well
plates using the methylene blue protein assay. Data are mean ± s.d.
(sextuplet wells) for percentage absorbance at 620 nm of control wells
numbers by about 10%, the combination of BB94, aprotinin,
pepstatin and E64 (B+A+P+E) had a dramatic cytostatic effect,
significantly reducing the cell population by over 60% under SC
conditions and by over 30% in SF medium (Table 3). The experi-
ment in which all combinations of these four inhibitors were
studied demonstrated that this effect was almost entirely due to the
combination of BB94 and E64, with aprotinin and pepstatin
making little or no contribution. Combinations of BB94 with
EACA (83 ± 12%, n = 3), tranexamic acid (85 ± 9%, n = 3) or
amiloride (70 + 21%, n = 3) resulted in some reduction in mean
cell growth in SC medium, but not with Ab-uPA (100 ± 11%, n =
3). Amiloride also reduced proliferation ofMCF7DOX cells (79 ±
5%, n = 3; control = 77 ± 16 x 103 cells per well, n = 15), but the
other inhibitors and combinations studied were without effect,
although B+A+P+E was not evaluated.
The effect ofBB94 plus E64 (or E64d) was furtherevaluated in
an experiment in which MDA-MB-231 cells were seeded into
uncoated wells and growth determined by the methylene blue
assay. As shown in Figure 5, there is an obvious dose response for
both cysteine proteinase inhibitors, with approximately 60%
reduction in cell growth at 100 FM when combined with BB94,
confirming the observations made with BM-coated wells.
DISCUSSION
The BMD assay used was modified from the original procedure
described by Yee and Shui (1986). Forcomparison ofdifferent cell
lines, these workers adjusted the amount of radioactivity released
from the BM to that produced by 105 cells, although details ofthis
manipulation were not reported. We found that adjustment for cell
proliferation involving logarithmic transformation gave a measure
of BMD that was independent of incubation time (48-120 h) and
cell population above 20 x 103, i.e. the seeding density. Thus, a
complete cytostatic effect of an agent under study would still
enable reliable evaluation ofchanges in BMD.
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Comparison ofthe different breast cancer cell lines studied with
this in vitro model showed that MDA-MB-231 cells exhibited the
highest levels of BM degradation, a finding consistent with that
reported by Yee and Shui (1986). In contrast, we found that the
ER-positiveMCF7VT, T47D and ZR75 cells had very low levels of
BMD. Our observations are consistent with the in vivo behaviour
of the cell lines; MDA-MB-231 and Hs578T cells are locally
invasive in nude mice and may form metastases, whereas the ER-
positive cell lines, at best, form primary tumours only with no
invasive features (Thompson etal, 1992; Bruinner et al, 1993). Our
findings with the BMD assay are also in close agreement with
results using the matrigel invasion model. Ofcell lines used in our
study, MDA-MB-231 and Hs578T cells showed the highest
matrigel invasion, while MCF7DOX cells were more invasive than
MCF7v, ZR75 and T47D cells (Thompson et al, 1992). Yee and
Shui (1986) reported greater cell-associated BMD by SF medium
than SC medium, afinding clearly at variance with our results. The
reasons for the various discrepancies between our observations
and those ofYee and Shui (1986) are notobvious,but may relate to
the differences in experimental procedure and method of determi-
nation of BMD. These workers used 10% FCS in the SC medium,
a 48-h incubation period and, apart from preliminary experiments,
used bovine corneal endothelial cells. A lower level of amnion
invasion by murine melanoma cells in the absence of serum has
previously been reported (Mignatti et al, 1986).
It has been suggested that cathepsin D may be a major
proteinase involved in breast cancer cell invasion (Briozzo et al,
1988; Garcia et al, 1990) following activation ofthe proenzyme in
intracellular 'acid microenvironments' (Montcourrier et al, 1990).
Relatively high levels of cellular and secreted immunoreactive
cathepsin D are found in MDA-MB-231 cell cultures (Isgar et al,
1991), and we observed here that serum-free conditioned medium
from these cells exhibited pepstatin-sensitive degradation of BM
only at pH 4.5, confirming an earlier report (Briozzo et al, 1988).
However, pepstatin at 100 tM had no effect on cell-associated
BMD, although it should be noted that this inhibitor has a reduced
affinity for cathepsin D at neutral pH (Barrett, 1977). PD 134678-
0073, which is freely soluble in water, was also without effect even
though the concentration used (10 [tM) was sixty times its IC50
value for cathepsin D (Doherty et al, 1992). This lack of evidence
of a direct role for cathepsin D in breast cancer cell invasion is
consistent with a recent reportusing the Matrigel invasion assay to
study a variety ofMCF7 cell clones (Johnson et al, 1993).
Cysteine proteinase inhibitors produced a modest suppression
of amnion membrane invasion by metastasizing murine mammary
adenocarcinoma cells (Yagel et al, 1989), and increased cathepsin
L mRNA in cell lines cloned from a peritoneal murine mammary
tumour was associated with increased invasiveness using the
matrigel assay (Morris et al, 1993). Furthermore, cathepsin B has
recently been shown to be secreted in an active form following
intracellular translocation to the cell periphery in three different
malignant cell lines, including the c-Ha-ras-transfected MCF-10
human breast epithelial cell line (Rozhin et al, 1994). Under
similar experimental conditions and concentrations of E64 as in
the present study, a substantial reduction of matrigel invasion by
ER-negative HOC-1 ovarian cancer cells has been reported
(Kobayashi et al, 1992). Although in our study E64 appears to
enhance the effect of pepstatin and BB94, the absence of any
consistent and major effect of E64 on BMD by MDA-MB-231 or
MCF7DOX cells suggests that cysteine proteinases probably play
only a minor role in the BM degradation by ER-negative human
breast cancer cells. Inhibition ofmotility ofhuman melanoma and
rat carcinosarcoma cells by cysteine proteinase inhibitors,
including E64, has been observed (Boike et al, 1991), and this
might account for some of the observations with amnion and
matrigel models.
In contrast to the minor effects of lysosomal proteinases,
inhibitors of uPA or plasminogen activation under SC conditions
caused significant reductions in BMD. We have shown directly that
the essential serum factor is plasminogen and that inhibition of its
conversion to plasmin by uPA with an anticatalytic uPA antibody
totally abolishes its effect. As uPA is preferentially activated when
bound to its receptor at the cell surface (Ellis and Dano, 1992), the
serine proteinase activity on BM might be expected to be largely
cell associated, and indeed Yee and Shui (1986) suggested that cell
contact was essential for BMD as they observed no activity
with SC-CM generated by cell culture on plastic. In our study, SC-
CM exhibited appreciable BM degradation that was completely
and exclusively inhibited by aprotinin, suggesting that non-cell-
associated BM degradation is mediated by the uPA/plasmin
system. Interestingly, we observed that, while SC-CM from MDA-
MB-231 cells grown on BM had approximately 20% of the BMD
activity obtained with the cells, SC-CM from cultures ofMCF7DOX
cells accounted for almost 80% ofthe cell-associated activity. This
cell line also had a somewhat different inhibitory profile, which
might reflect its drug resistance phenotype.
The importance of uPA/plasmin in the in vitro invasion of
various non-breast cancer cell lines has been well described
(Mignatti et al, 1986; Kobayashi et al, 1992; Reiter et al, 1993).
Aprotinin, tranexamic acid and amiloride have all been reported to
have antimetastatic effect in vivo, including use in the treatment of
cancer patients (Kikuchi et al, 1986, 1987; Kellen et al, 1988;
Uetsuji et al, 1992). Although it has been known for some years
that MDA-MB-231 cells express much higher levels of uPA than
the non-invasive MCF7WT cells (Mangel et al, 1988), we believe
the present study is the first to provide direct experimental
evidence of a role for uPA in the degradation of BM by breast
cancer cells. Our findings are consistent with the recent report of
Holst-Hansen et al (1996) in which matrigel invasion by MDA-
MB-231 BAG cells was inhibited by antibodies to uPA or uPA
receptor (uPAR). These workers also demonstrated that, in
contrast to MCF-7 BAG and MDA-MB-435 BAG cells, the MDA-
MB-231 BAG cell line expressed high protein levels of uPA and
uPAR and was consequently highly active in generating plasmin;
the latterbeing abolished by the uPA and uPAR antibodies. Further
study of inhibitors of uPA and plasminogen activation as
antimetastatic drugs in the treatment of breast cancer would seem
to be warranted.
There is good circumstantial evidence for a potential role for
MMPs in breast cancer invasion from both tumour homogenate
and immunohistochemical studies (Monteagudo et al, 1990;
Davies et al, 1993a). Treatment of mice bearing human ovarian
cancer xenografts with the broad spectrum MMP inhibitor BB94
(Batimastat) reduced tumour burden and increased survival
(Davies et al, 1993b). In a more recent study, BB94 reduced the
incidence oflocal tumourrecurrence and formation oflung metas-
tases when administered to nude mice after resection of MDA-
MB-435 primary tumours (Sledge et al, 1995). This effect was not
associated with changes in the tumour expression of MMPs or
TIMP-2. We have shown that BB94 significantly reduces MDA-
MB-231 cell-associated BMD under both SC and SF conditions.
Furthermore, with these cells, the MMP activity appears to be
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solely cell-associated, in that we observed no effect of BB94 on
BM degradation by SC-CM.
Full details ofthe different MMPs expressed by these cell lines
have yet to be described, and it is possible that one or more species
are involved. MDA-MB-231 andMCF7DOX cells have been shown
to lack endogenous production of MMP-2 (pro-gelatinase A,
72-kDa type IV collagenase), although they can activate pro-
MMP-2 of serum origin trapped in culture matrix containing
collagen I (Azzam et al, 1993). However, as BB94 reduced BMD
under SF conditions, our data suggests that other MMPs, such as
interstitial collagenases or stromelysins, may be involved.
However, in tumours, MMPs ofstromal origin may play an impor-
tantrole. While TIMP-2 has apreference forcomplexing with pro-
MMP-2, it can inhibit most active MMPs (DeClerck and Imren,
1994). Nevertheless, in this study, TIMP-2 had only a modest
inhibitory effect on BMD by MDA-MB-231 cells, particularly in
comparison with BB94.
It has been proposed that activation of MMPs is brought about
by plasmin, being the final step in a proteolytic cascade (Mignatti
et al, 1986; Reich et al, 1988; Schmitt et al, 1992). However, for
the breast cancer cells studied, we found little to suggest that the
MMP activity was dependent upon uPA/plasmin activation;
BB94 reduced 'absolute' BMD values by very similar amounts
under SC and SF conditions, and combination with inhibitors of
uPA/plasminogen activation, in the presence of serum, had an
additive effect. Indeed, the latter observation suggests that
MMPs and uPA/plasminogen activation act independently in
breaking down BM as others have proposed (Mignatti et al,
1986; Lim et al, 1996).
The relatively small reductions in cell proliferation seen with
BB94 and amiloride are probably related to some non-specific
cytotoxicity. TIMP-2 produced a similar decrease in cell numbers
which might represent a more specific inhibition of cell growth
(DeClerck and Imren, 1994), although growth stimulation by
TIMP-2 has also been observed (Hayakawa et al, 1994; Nemeth et
al, 1996). The profound reduction of cell proliferation with the
combination ofBB94 and the cysteine proteinase inhibitors E64 or
E64d is surprising in view of the minimal effect of the two
inhibitors separately. E64d is a membrane-permeant derivative of
E64 and is an ethyl ester that is converted under cell culture condi-
tions to the more potent inhibitor Ep475 (Shoji-Kasai et al, 1988).
Thus, cell uptake and greater potency of inhibition do not appear
to be important factors in this phenomenon. The effects of the
combination ofBB94 and E64 or E64d may represent stablization
of one inhibitor by the other, although BB94 is very stable under
the cell culture conditions used (Dr P D Brown, personal commu-
nication). E64d has been shown to arrest human epidermoid carci-
noma A431 cells at mitotic metaphase (Shoji-Kasai et al, 1988),
and it is possible that inhibition of a key cysteine proteinase-
dependent process in cell division is in some way enhanced by
MMP inhibition. Clearly, further study into the mechanisms
involved is required.
In conclusion, inhibitors of uPA/plasminogen activation and
MMPs may be of potential therapeutic value in human breast
cancer. BB94 and related MMP inhibitors are currently under-
going clinical trials in patients with advanced disease. There is
also interest in developing highly specific and sensitive inhibitors
of uPA as antimetastatic agents (Towle et al, 1993). Combined
inhibition of uPA/plasminogen activation and MMP as anti-
metastatic therapy for patients with breast cancer deserves clinical
evaluation.
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